seekingalpha.com
/1 month ago
Latest updates for Fhrrx
Fresh curated links around FHRRX are collected here so marketers can spot useful updates and turn timely ideas into posts faster.
Recent items include:
- Fenix Resources Limited (FEXRF) Q4 2026 Earnings Call Transcript
- <![CDATA[Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data]]>
- Olema: Best Breast Cancer Therapy, Or SERD Also-Ran? We'll Find Out In Q1 '27
Post angles to try
Share the most useful takeaway for your audience.
Turn one article into a quick practical checklist.
Ask your audience how this shift affects their work.
Fresh articles and ideas
Recent curated links from global sources. Generate one free draft from any story, then use SocialBu to schedule and refine your content calendar.
pharmexec.com
/2 weeks ago
<![CDATA[Foghorn Therapeutics & Eli Lilly Halt Fhd-909 Development Following Phase I Data]]>
seekingalpha.com
/1 month ago
Olema: Best Breast Cancer Therapy, Or SERD Also-Ran? We'll Find Out In Q1 '27
fool.com
/1 week ago
Better Buy: Fidelity Health Care ETF (FHLC) or iShares Biotechnology ETF (IBB)?
FHLC offers broader sector exposure at a 0.08% expense ratio, compared with IBB's concentrated biotech focus at 0.44%, but IBB delivered stronger 1-year returns despite higher vola...
pharmexec.com
/2 weeks ago
<![CDATA[Pharmaceutical Executive Daily: Foghorn Therapeutics & Eli Lilly Discontinue Development of FHD-909]]>...
fool.com
/1 week ago
Stock Market Today, Oct. 13: Fermi Surges 14% on AMD Credit Support for Project Matador
AMD's backing of Fermi's 222 MW lease signals financing momentum for AI campus infrastructure, though full funding hurdles remain ahead, Oct. 13, 2026.
biopharmadive.com
/1 month ago
Skyhawk racks up more support for Huntington’s drug
The Fidelity-backed biotech now has 15-month data from a small study of its RNA-splicing therapy.
letlifehappen.com
/1 month ago
FDA Grants Fast Track Designation to ETX-19477 in BRCA-Mutated HR+/HER2– Breast Cancer
From: .onclive.com The FDA has granted fast track designation to ETX-19477 for the treatment of adult patients with BRCA-mutated, hormone receptor (HR)–positive, HER2-negative unre...
ttnews.com
/2 weeks ago
C.H. Robinson to acquire RXO for $5.8 billion
RXO shareholders will receive $17.25 in cash and 0.0856 share of C.H. Robinson for each RXO share they own, for an implied consideration of $30.25 a share.
seekingalpha.com
/3 weeks ago
Aldeyra Therapeutics, Inc. (ALDX) Discusses FDRR and FDA Review Process for Reproxalap in Dry Eye Disease - Slideshow
seekingalpha.com
/1 week ago
Nurix: Maintaining 'Strong Buy' Updated Bexobrutideg Data CLL/SLL And Multiple Advancement Pathways
Turn fresh research into a full content calendar
Use SocialBu to discover ideas, generate post drafts, and schedule them across your social channels.
Sources covering Fhrrx
seekingalpha.com
Recent coverage from public sources
Public source
feeds.feedburner.com
Recent coverage from public sources
Public source
seekingalpha.com
Recent coverage from public sources
Public source
seekingalpha.com
Recent coverage from public sources
Public source
biopharmadive.com
Recent coverage from public sources
Public source
fool.com
Recent coverage from public sources
Public source